Skip to main navigation
  • Our Company
    • About Us
    • Executive Team
    • Board of Directors
    • Scientific and Clinical Advisors
    • Partners
  • Our Science
    • Overview
    • CD6-ALCAM Pathway
    • Itolizumab
    • Publications & Presentations
  • Pipeline
    • Overview
    • Pipeline Graphic
    • Clinical Trials
  • Patients
    • Therapeutic Areas
      • Graft-Versus-Host Disease
      • Uncontrolled Moderate to Severe Asthma
      • SLE / Lupus Nephritis
    • Clinical Trials
      • The EQUATE study
      • The EQUIP study
      • The EQUALISE study
  • Investors
    • Investor Overview
    • Stock Quote & Chart
    • Historical Price Lookup
    • News
    • Events & Presentations
    • Analyst Coverage
    • SEC Filings
    • Governance Highlights
    • Committee Composition
    • Investor FAQ
    • Alerts & Contacts
  • Careers
  • Contact Us
    Equillium Bio
    • Our Company
      • About Us
      • Executive Team
      • Board of Directors
      • Scientific and Clinical Advisors
      • Partners
    • Our Science
      • Overview
      • CD6-ALCAM Pathway
      • Itolizumab
      • Publications & Presentations
    • Pipeline
      • Overview
      • Pipeline Graphic
      • Clinical Trials
    • Patients
      • Therapeutic Areas
        • Graft-Versus-Host Disease
        • Uncontrolled Moderate to Severe Asthma
        • SLE / Lupus Nephritis
      • Clinical Trials
        • The EQUATE study
        • The EQUIP study
        • The EQUALISE study
    • Investors
      • Investor Overview
      • Stock Quote & Chart
      • Historical Price Lookup
      • News
      • Events & Presentations
      • Analyst Coverage
      • SEC Filings
      • Governance Highlights
      • Committee Composition
      • Investor FAQ
      • Alerts & Contacts
    • Careers
    • Contact Us

    SEC Filing Details

    Investor Relations

    • Investor Overview
    • Stock Quote & Chart
    • Historical Price Lookup
    • News
    • Events & Presentations
    • Analyst Coverage
    • SEC Filings
    • Governance Highlights
    • Committee Composition
    • Investor FAQ
    • Alerts & Contacts

    SEC Filing Details

    Document Details

    Form
    10-Q
    Filing Date
    Aug 12, 2019
    Document Date
    Jun 30, 2019
    Form Description
    Quarterly report which provides a continuing view of a company's financial position
    Filing Group
    Quarterly Filings
    Company
    Equillium
    Issuer
    Equillium, Inc.

    Filing Formats

    View HTML
    Download PDF
    Download DOC
    Download XLS

    XBRL

    XBRL Viewer
    EX-101.INS - XBRL INSTANCE DOCUMENT
    EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
    EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
    EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
    EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE
    EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
    2021 © Equillium, Inc. EDPO Certification | Privacy Notice
    Scroll to top